Fulcrum Therapeutics (FULC) Total Current Liabilities (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Total Current Liabilities data on file, last reported at $9.9 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 21.78% year-over-year to $9.9 million in Q1 2026; TTM through Mar 2026 was $9.9 million, a 21.78% increase from a year earlier, with the FY2025 full-year figure at $13.0 million, up 18.15% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $9.9 million, down from $13.0 million in the prior quarter.
• Over the last five years, Total Current Liabilities for FULC reached as high as $22.1 million in Q2 2022 and fell as low as $8.1 million in Q1 2025.
• Historically, Total Current Liabilities has averaged $13.5 million across 5 years, with a median of $13.7 million in 2023.
• Across the five-year window, Total Current Liabilities sank 33.08% in 2023 and grew 21.78% in 2026, its largest moves.
• Year by year, Total Current Liabilities stood at $16.7 million in 2022, then dropped by 18.24% to $13.7 million in 2023, then fell by 19.24% to $11.0 million in 2024, then advanced by 18.15% to $13.0 million in 2025, then decreased by 24.4% to $9.9 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $9.9 million in Q1 2026, $13.0 million in Q4 2025, and $11.6 million in Q3 2025.